Evaluate

Name

Evaluate

Legal name

Evaluate, a Norstella Company

Website

https://evaluate.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Commercial Intelligence

NAICS

Other Scientific and Technical Consulting Services (54169)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Pharmaceutical commercial intelligence
• Drug pipeline forecasting
• Biopharma market analysis
• Consensus drug forecasting
• Pharma competitive intelligence

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Subscription data products: Recurring subscriptions to SaaS/data platforms including Evaluate Pharma, Evaluate Omnium, Evaluate Epi, Biomedtracker, Datamonitor Healthcare, BioSciDB, Meddevicetracker, FC+, FC365, Evaluate Medtech, Japan & Europe Drug Forecasts, Norstella Atlas CI, CDMO Intelligence, and Real World Data feeds. Built around licensed datasets delivered via web app login.
2. Consulting & analytics services: Tailored advisory engagements (over 70 consultants globally) across portfolio strategy, BD&L, competitive intelligence and market sizing/forecasting. Includes Custom Model Build, Forecasting Support, and the Forecasting Audit service.
3. Disease Reports (one-time report sales): One-time purchase of in-depth disease reports from the Report Store (e.g., Chronic Urticaria Disease Report priced at $16,275) covering oncology, immunology, CNS, gastroenterology, and cardiovascular/metabolic indications.
4. Training and enablement services: Pharma forecasting training delivered as tailored in-person workshops, online self-paced courses, and multi-client workshops; complementary to product subscriptions.

Pricing tiers

Go-to-market motion4 records

Core offering

Evaluate delivers AI-augmented commercial intelligence and advisory services to pharmaceutical, biotech, and life science investors. Its core offering is a portfolio of subscription data platforms (Evaluate Pharma consensus forecasts, Evaluate Omnium ML-driven pipeline forecasting, Evaluate Epi epidemiology, Biomedtracker, Datamonitor Healthcare, BioSciDB, Norstella Atlas CI) combined with a 70+ consultant professional services practice covering portfolio strategy, BD&L, competitive intelligence, and bespoke pharma forecasting model builds.

Product overview

Evaluate (a Norstella company) delivers a platform-plus-modules architecture of commercial intelligence products for the pharmaceutical industry, organised around four solution areas: Forecasting, Business Development & Licensing, Portfolio Strategy, and Competitive Intelligence. The flagship core product is Evaluate Pharma, the consensus-forecasting platform that anchors the portfolio and feeds downstream tools. Layered on top are Evaluate Omnium (ML-driven pipeline forecasting using PTRS and NPV models), Evaluate Epi (epidemiology intelligence covering 530+ diseases and 14,500+ sub-populations), regional consensus forecasts for Japan and Europe, and the Ask Ella AI analyst embedded in Evaluate Pharma and Biomedtracker. Pipeline and deal intelligence is provided through Biomedtracker, Datamonitor Healthcare, BioSciDB, and the Norstella Atlas CI agentic-AI platform. Forecasting enablement is delivered via the FC365 cloud-based platform and the FC+ Excel-based suite (with Sales+, Epi+, Onco+, and Flow+ add-ins), supplemented by the J+D Forecasting custom model build, training, and Pharma Forecasting Support services inherited from the 2024 J+D acquisition. Specialised data products include Meddevicetracker, Evaluate Medtech, CDMO Intelligence, Real World Data, and Data Feeds. A global consulting and analytics practice (70+ consultants) wraps around the data products to deliver Custom Analytics, Competitive Intelligence, and bespoke Portfolio Strategy, BD&L, and Forecasting engagements.

Differentiator

Problem solved

Functional benefit

Brands

• Evaluate Pharma: Premier consensus-forecasting platform for the biopharma industry, covering nearly 6,000 drugs with 1.5m+ historical forecasts.
• Evaluate Omnium
• Evaluate Epi
• Biomedtracker
• Datamonitor Healthcare
• Norstella Atlas CI
• BioSciDB
• Ask Ella
• J+D Forecasting
• Japan Drug Forecasts
• Europe Drug Forecasts

Products and services

• Evaluate Pharma Premier consensus-forecasting platform for the biopharma industry, covering almost 6,000 drugs with 1.5m+ historical forecasts of 10,000 products dating back to 2003. Connects consensus forecasts with pipelines across indications, therapeutic areas, and mechanisms of action to support BD&L, competitive intelligence, and commercial strategy for pharmaceutical and biotech customers.
• Evaluate Omnium Machine-learning platform that analyses millions of data points across the full clinical pipeline, including early-phase and privately-held assets, to deliver risk-adjusted peak sales, NPV modelling, PTRS scores, and ROI benchmarks for pipeline prioritisation and capital allocation.
• Evaluate Epi Evidence-based epidemiology intelligence covering 15 therapeutic areas, 530+ indications and 14,500+ sub-populations across 55 countries, providing patient segmentation, prevalence, and incidence data to underpin asset valuations and forecasts for pharma and biotech customers.
• Japan Drug Forecasts Consensus forecasts, historical sales, and sales-by-indication for the Japanese pharmaceutical market, covering nearly 2,000 marketed and R&D products and over 80% of Japan's total market value.
• Europe Drug Forecasts Country- and product-level consensus forecasts out to 2030, plus R&D pipeline and ex-factory pricing across Germany, France, Italy, England, Poland, Spain, and other key EU markets.
• Ask Ella Generative-AI analyst embedded inside Evaluate Pharma and Biomedtracker that answers plain-English questions with sourced, citable responses drawn exclusively from the licensed Evaluate datasets the subscriber already trusts. Understands indications, modalities, deal structures, and forecast models and maintains conversation context across multi-turn Q&A.
• Norstella Atlas CI Agentic AI platform purpose-built for pharma competitive intelligence, running on Norstella's curated data lake. Reasons across master drugs, trials, events, and organisations datasets (and a customer's own data via BYOD) to deliver ready-to-share competitive landscapes, drug profiles, catalyst timelines, and leadership briefings exportable to editable PowerPoint, cutting approximately 80% of manual CI assembly time.
• Biomedtracker Real-time tracking of the drug development landscape covering over 35,000 drugs and 1,800+ targets, with proprietary Likelihood-Of-Approval (LOA) and predictive POA metrics, deal summaries, patent coverage, conference coverage, and analyst commentary for pharma and biotech customers.
• Datamonitor Healthcare In-depth market analysis across 130+ disease areas with KOL insights, patient and sales forecasts, SWOT analyses on the top 45 companies, regional breakdowns, and a proprietary Drug Assessment Model for marketed and pipeline therapies.
• BioSciDB Reference database of biopharma alliances containing three decades of publicly filed deals and over 11,100 unredacted contracts obtained via FOIA disclosures, with structured Alliance Keyword search and contract-level inspection tools to support BD&L deal benchmarking.
• Meddevicetracker Provides a 360-degree view of medical device markets, companies, and products, including upcoming filing alerts, clinical trial dates, trial data, and market size information for medical device and medtech customers.
• Evaluate Medtech Enables medtech users to gauge market perceptions of their own company and portfolio, as well as competitors, clients, and potential new partners in the medtech space.
• CDMO Intelligence Intelligence solution launched on October 3, 2023 to support the rapidly expanding pharmaceutical Contract Development & Manufacturing Organization (CDMO) market and inform CDMO partnership decisions.
• Real World Data Real-world data product referenced in Evaluate's product portfolio to support evidence-based pharmaceutical decision-making.
• Data Feeds Data feed product for delivering Evaluate's commercial intelligence into client systems, enabling integration of Evaluate datasets into customer workflows.
• FC365 Collaborative, cloud-based pharma forecasting platform built on the Microsoft 365 technology stack. Retains Excel as the native forecasting tool, integrates MS Teams collaboration and Power BI visualisations, and supports multi-scenario forecasting for global pharma teams.
• FC+ Pharma Forecasting Software Excel-based pharmaceutical forecasting suite comprising specialised add-ins (Sales+ for statistical revenue/unit/patient forecasting, Epi+ for epidemiology forecasts, Onco+ for oncology patient-flow forecasting, and Flow+ for patient flow in progressive diseases), with built-in Monte Carlo, SIMSCORE, P&L, and consolidation modules.
• J+D Forecasting Solutions Suite of pharmaceutical-industry forecasting solutions acquired by Evaluate in January 2024, integrating FC+, FC365, custom models, advanced analytics, training, and GenAI technology into the Evaluate portfolio.
• Competitive Intelligence (CI) Solution Tech-enabled competitive intelligence platform powered by Norstella data, featuring modules for Pipeline, Trial Timeline, Deals, Risk & Return, Conferences, Approval Timeline, Market Size, Events & Catalysts, and News Headlines, with presentation-ready auto-generated deliverables.
• Custom Model Build Bespoke Excel-based forecast model construction delivered by J+D's forecasting specialists, claimed to reduce development time by up to 80% and cost by up to 60% versus traditional custom builds, tailored to product lifecycle stage, disease area, and organisational processes.
• Pharma Forecasting Training Pharma forecasting training delivered by J+D's forecasting specialists, available as online self-paced courses, multi-client workshops, and tailored in-person workshops covering sales, oncology, and epi-based techniques.
• Pharma Forecasting Support On-demand consultancy and support from J+D's forecasting specialists for peak-period capacity, special projects, and Forecasting Audits, delivered by teams located in the US, Europe, and the UK.
• Custom Analytics (Consulting) Pharmaceutical consulting and analytics team of 70+ consultants delivering bespoke engagements across Business Development & Licensing, Asset & Portfolio Strategy, and Competitive Intelligence, leveraging Evaluate's data and Norstella's broader expertise.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability9 records

Feature8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• IQVIA: IQVIA is the largest life sciences commercial intelligence and clinical research provider globally, offering R&D solutions, real-world evidence, and technology. It competes with Evaluate across pharma commercial intelligence, market sizing, and forecasting, but operates at much greater scale across a broader portfolio.
• Veeva Systems: Veeva provides life sciences cloud software (CRM, Vault, Veeva Compass data) used across commercial, medical and R&D workflows. It competes indirectly with Evaluate by embedding commercial data, patient data and AI into pharma operating platforms rather than selling standalone intelligence subscriptions.
• S&P Global Market Intelligence: S&P Global Market Intelligence provides cross-sector financial and corporate data with healthcare-adjacent datasets. It is comparable as a broader commercial intelligence incumbent but lacks Evaluate's depth of pharma-specific drug, trial and forecast coverage.

Direct peers

• Clarivate: Clarivate provides pharmaceutical and biopharma intelligence (Cortellis, Drug Safety, BioWorld) and competes directly with Evaluate on drug pipeline, patent, deal and forecasting data used by life sciences enterprises. Both serve the same pharma BD&L, portfolio strategy and CI workflows with overlapping product categories.
• Citeline (Norstella): Citeline is a sister company of Evaluate under Norstella and provides clinical trial intelligence (TrialTrove, Sitetrove, PharmaProject) with deep coverage of trial design, sites, and outcomes. Both brands target the same pharma customer for pipeline and competitive intelligence but with complementary rather than overlapping datasets.
• Informa Pharma Intelligence: Informa Pharma Intelligence offers Citeline-derived trial and pipeline data plus Scrip, Meddevicetracker competitor insights and Pink Sheet regulatory intelligence. It competes directly with Evaluate's Biomedtracker and Evaluate Pharma in serving pharma strategy, BD&L and CI teams.
• GlobalData: GlobalData provides pharma market sizing, drug forecasts, epidemiology and company intelligence through its Pharma and Healthcare units. It overlaps directly with Evaluate Pharma, Evaluate Epi and Datamonitor Healthcare on consensus forecasts and disease-level market analysis.

Emerging players

• Definitive Healthcare: Definitive Healthcare provides U.S.-centric healthcare commercial intelligence covering providers, payers and life sciences accounts. It is comparable as a pharma commercial intelligence platform but skews more toward U.S. healthcare provider and account data than Evaluate's global drug-and-pipeline focus.
• AlphaSense: AlphaSense is an AI-driven market intelligence and enterprise search platform used by life sciences strategy and CI teams. It is comparable to Ask Ella and Norstella Atlas CI as an AI-augmented research layer but sources primarily from broker research and public documents rather than Evaluate's licensed pharma datasets.
• CBPartners: CBPartners is a boutique pharma pricing, market access and value strategy consultancy that directly competes with Evaluate's Consulting & Analytics practice for BD&L, pricing, and forecasting engagements with global pharma clients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/evaluatepharma
• LinkedInlinkedin.com/company/evaluatepharma
• Instagraminstagram.com/evaluateltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries14 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evaluate